Premium Nahrungsergänzungsmittel | artgerecht

Granulomatosis with Polyangiitis (GPA) – Overview

Granulomatosis with polyangiitis (GPA) is a rare autoimmune disease causing inflammation of blood vessels and granuloma formation in organs such as the nose, lungs, and kidneys.

Regular tips about health Regular tips about health

Things worth knowing about "Granulomatosis with Polyangiitis"

Granulomatosis with polyangiitis (GPA) is a rare autoimmune disease causing inflammation of blood vessels and granuloma formation in organs such as the nose, lungs, and kidneys.

What is Granulomatosis with Polyangiitis?

Granulomatosis with polyangiitis (GPA) – formerly known as Wegener granulomatosis – is a rare, chronic, inflammatory autoimmune disease. It belongs to the group of ANCA-associated vasculitides, meaning the immune system attacks the body's own blood vessels. The disease is characterized by the formation of inflammatory nodules called granulomas and inflammation of small to medium-sized blood vessels (vasculitis). It primarily affects the upper and lower airways and the kidneys, but can involve nearly any organ in the body.

Causes

The exact cause of GPA is not yet fully understood. It is an autoimmune disease in which the immune system becomes dysregulated and attacks the body's own tissues. The following factors are under discussion:

Genetic predisposition: Certain genetic characteristics are associated with increased risk.
Infections: Bacterial infections, particularly with Staphylococcus aureus, are considered possible triggers.
Immune dysfunction: GPA is frequently associated with ANCA antibodies (anti-neutrophil cytoplasmic antibodies), especially c-ANCA directed against proteinase 3 (PR3), which trigger inflammatory reactions in vessel walls.
Environmental factors: Exposure to certain chemicals or dust particles has been considered as a possible risk factor.

Symptoms

The symptoms of GPA are diverse and depend on which organs are affected. Common manifestations include:

Upper Airways

Chronic nasal congestion or nosebleeds
Sinus pain and pressure (sinusitis)
Hoarseness or difficulty swallowing due to laryngeal involvement
In advanced stages: destruction of the nasal septum resulting in a saddle nose deformity

Lungs (Lower Airways)

Cough, sometimes with bloody sputum (hemoptysis)
Shortness of breath and dyspnea
Pulmonary infiltrates or nodules visible on imaging

Kidneys

Blood in the urine (hematuria)
Protein in the urine (proteinuria)
Reduced kidney function, potentially progressing to kidney failure

General Symptoms

Fatigue and general malaise
Fever and night sweats
Unintentional weight loss
Joint and muscle pain

Other Possible Organ Manifestations

Eyes: redness, pain, visual disturbances (episcleritis, uveitis)
Skin: skin hemorrhages (purpura), ulcerations
Nervous system: numbness, weakness (peripheral neuropathy)

Diagnosis

Diagnosing GPA requires a combination of clinical examination, laboratory testing, and tissue sampling:

Blood tests: Detection of c-ANCA/PR3-ANCA antibodies (positive in approximately 80–90% of patients with active GPA), inflammatory markers such as CRP and ESR, complete blood count, and kidney function tests
Urinalysis: Detection of blood or protein in the urine as indicators of kidney involvement
Imaging: Chest X-rays and CT scans of the lungs and sinuses to identify granulomas and areas of inflammation
Biopsy: Tissue sampling (e.g., from the nasal mucosa, lung, or kidney) for direct confirmation of granulomas and vasculitis
Kidney biopsy: Used when renal involvement is suspected to assess the extent of damage

Diagnosis is also guided by the classification criteria of the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR).

Treatment

GPA is a serious condition that can be life-threatening without treatment. The goals of therapy are to induce remission (reduce disease activity) and to maintain it long-term.

Remission Induction

Rituximab: A monoclonal antibody that depletes B cells of the immune system. It is now considered a standard therapy, especially for severe disease.
Cyclophosphamide: An immunosuppressant used primarily in life-threatening manifestations.
Glucocorticoids (corticosteroids): Used at high doses in combination to rapidly suppress inflammation.

Remission Maintenance

Rituximab (every 6 months) or azathioprine and methotrexate to prevent relapses
Glucocorticoids are gradually tapered over time.

Additional Measures

Regular monitoring of kidney function, blood pressure, and ANCA levels
Infection prophylaxis (e.g., against Pneumocystis jirovecii) during immunosuppressive therapy
Nephrology co-management or dialysis if kidney function is significantly impaired

Prognosis

With modern immunosuppressive therapy, the prognosis of GPA has improved significantly. Many patients achieve long-term remission. However, relapses are common, making regular medical follow-up essential. Without treatment, the disease was historically fatal within months. Early diagnosis and consistent therapy are therefore critical to improving outcomes.

References

Jennette JC et al. - 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11.
Yates M et al. - EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-1594.
Falk RJ, Gross WL - Granulomatosis with Polyangiitis (Wegener's). UpToDate, Wolters Kluwer. 2023.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category